AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease
16 mars 2023 08h45 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., March 16, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease
08 mars 2023 08h45 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., March 08, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech Issues Letter to Stockholders
06 mars 2023 08h45 HE
|
AIM ImmunoTech Inc.
Year marked by noteworthy operational execution and clinical development progress across pipeline Company reiterates commitment to continued communication and activity with the investment and...
AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients
28 févr. 2023 08h45 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, “Long Covid: What Will It Take To Accelerate Therapeutic Progress?”
17 févr. 2023 08h55 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Feb. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center
17 janv. 2023 08h45 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Jan. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIMイムノテック (AIM ImmunoTech)、アストラゼネカ (AstraZeneca) およびエラスムスメディカルセンター (Erasmus Medical Center) と、膵臓がんに関する臨床研究契約を締結
17 janv. 2023 08h45 HE
|
AIM ImmunoTech Inc.
フロリダ州オカラ発, Jan. 17, 2023 (GLOBE NEWSWIRE) -- 複数のタイプのがんや免疫障害、ウイルス性疾患 (SARS-CoV-2ウイルスが原因で発症する新型コロナウイルス感染症を含む) の治療法の研究開発に注力する免疫製薬会社であるAIMイムノテック (AIM ImmunoTech Inc: AIM)...
AIM ImmunoTech与AstraZeneca和伊拉斯谟医疗中心签订胰腺癌临床研究协议
17 janv. 2023 08h45 HE
|
AIM ImmunoTech Inc.
佛罗里达州奥卡拉, Jan. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc.（纽约证券交易所代码：AIM）（以下简称“AIM...
AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevention
09 janv. 2023 08h05 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Jan. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech to Present at the ‘Virtual Investor 2023 Companies to Watch Event’
05 janv. 2023 08h45 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Jan. 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...